ClinicalTrials.gg
CompletedNCT04608344Updated Jun 14, 2022Results posted

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants

A Phase 1 interventional study of Atorvastatin and Pravastatin in Rheumatoid Arthritis, sponsored by Gilead Sciences. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-14.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.

Enrollment
16th of 17
27 · median 287
Started
2020
the only one that year
Phase 1
2 of 17
none open now
Registered
12th of 17
by date
Lead sponsor
5 of 17
Gilead Sciences

Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 16th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1, and was the 12th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About GLPG0634

GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing GLPG0634 in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of filgotinib on a mixed organic anion transporting polypeptide/cytochrome P450 3A (OATP/CYP3A), OATP/ breast cancer resistance protein (BCRP), and OATP substrates using phenotypic probes.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Be a nonsmoker. The use of nicotine or nicotine-containing products must be discontinued 90 days prior to the first dose of study drug.
  • Have a calculated (BMI) of greater than or equal to (≥) 19.0 and less than or equal to (≤) 30.0 kilogram per meter square (kg/m\^2) at screening.
  • Have a (CLcr) ≥ 90 milliliters per minute (mL/min) (using the Cockcroft-Gault method) based on serum creatinine and actual body weight as measured at screening and upon admission.
  • Female participants of must have a negative serum pregnancy test at screening and a negative urine pregnancy test at clinic admission.
  • Male participants must be surgically sterile.
  • Male participants and female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of .
  • Screening laboratory evaluations and 12-lead (ECG) evaluations must be without abnormalities as assessed by the investigator.
  • Have liver biometric tests such as (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total below the at screening.
  • Must be willing and able to comply with all study requirements.
  • Must, in the opinion of the investigator, be in good health based upon medical history and physical examination, including vital signs.
  • Participants must not have donated blood within 56 days of study entry or plasma within 7 days of study entry and must refrain from blood donation from clinic admission, throughout the study period, and continuing for at least 30 days following the last dose of study drug.

Key Exclusion Criteria:

  • Positive serum pregnancy test (Female participants).
  • Lactating female.
  • Have received any drug/device within 30 days prior to study dosing (or within 5 half-lives of the drug, whichever is longer).
  • Have current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance or participant safety, or a positive drug or alcohol test at screening or admission.
  • Have a positive test result for type 1 (HIV-1) antibody, virus (HBV) surface antigen (HBsAg), or virus (HCV) antibody at screening.
  • Have positive Coronavirus Disease 2019 (COVID-19) Real-Time Reverse.
  • Transcriptase-Polymerase Chain Reaction (RT-PCR) testing on screening and admission.
  • Have poor venous access that limits phlebotomy.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Sequence AB

    Participants will receive atorvastatin (ATV) 40 mg tablet on Day 1, followed by a washout period of 1 day, and then pravastatin (PRA) 40 mg + rosuvastatin (ROS) 10 mg tablets on Day 3 in Treatment A, Period 1. In Treatment B, Period 2 participants will receive filgotinib 200 mg tablet once daily for 11 days, with ATV 40 mg on Day 12 and PRA 40 mg + ROS 10 mg tablets on Day 14. Period 1 and Period 2 will be separated by a washout period of 3 days.

    Drug: Atorvastatin · Drug: Pravastatin · Drug: Rosuvastatin · Drug: Filgotinib

  • Experimental
    Sequence BA

    Participants will receive filgotinib 200 mg tablet once daily for 11 days, with ATV 40 mg on Day 6 and PRA 40 mg + ROS 10 mg tablets on Day 8 in Treatment B, Period 1. In Treatment A, Period 2 participants will receive ATV 40 mg tablet on Day 18, followed by a washout period of 1 day and PRA 40 mg + ROS 10 mg tablets on Day 20. Period 1 and Period 2 will be separated by a washout period of 6 days.

    Drug: Atorvastatin · Drug: Pravastatin · Drug: Rosuvastatin · Drug: Filgotinib

Interventions

  • Administered as single dose tablet orally.

  • Administered as single dose tablet orally.

  • DrugRosuvastatin

    Administered as single dose tablet orally.

  • Administered as tablet orally once daily for 11 days.

    Also known as: GS-6034, GLPG0634, Jyseleca

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: AUClast of ATV, PRA, and ROS

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: AB (Days 1,3,12,14) and BA (Days 6,8,18,20): Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 postdose; AB (Days 1,12) and BA (Days 6,18): 5,10,36 hours post dose; AB (Days 3,14) and BA (Days 8,20): 72 hours postdose

  2. PK Parameter: AUCinf of ATV, PRA, and ROS

    AUCinf is defined as the concentration of drug extrapolated to infinite time.

    Time frame: AB (Days 1,3,12,14) and BA (Days 6,8,18,20): Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 postdose; AB (Days 1,12) and BA (Days 6,18): 5,10,36 hours post dose; AB (Days 3,14) and BA (Days 8,20): 72 hours postdose

  3. PK Parameter: Cmax of ATV, PRA, and ROS

    Cmax is defined as the maximum observed concentration of drug.

    Time frame: AB (Days 1,3,12,14) and BA (Days 6,8,18,20): Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 postdose; AB (Days 1,12) and BA (Days 6,18): 5,10,36 hours post dose; AB (Days 3,14) and BA (Days 8,20): 72 hours postdose

Secondary outcomes

  1. Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant administered a study drug, which did not necessarily have a causal relationship with the treatment. AE was therefore any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug. TEAEs: AE with an onset date on or after the study drug start date and no later than 30 days after study drug stop date; or any AE leading to study drug discontinuation.

    Time frame: Sequence AB: First dose up to 47 days, Sequence BA: First dose up to 50 days

  2. Percentage of Participants With Severity Grade 3 or Above Treatment-Emergent Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were graded using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 of Adverse Events and Laboratory abnormalities. Laboratory abnormalities were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Life-threatening), Grade 5 (Death). Percentage of participants with Grade 3 or higher treatment-emergent laboratory abnormalities were reported.

    Time frame: Sequence AB: First dose up to 47 days, Sequence BA: First dose up to 50 days

07

Results

Posted Jan 19, 2022

Participant flow

Participants were enrolled at a study site in the United States. The first participant was screened on 04 November 2020. The last study visit occurred on 13 January 2021.

Period 1 (AB: 3 Days, BA: 11 Days)
Participant flow — Period 1 (AB: 3 Days, BA: 11 Days)
MilestoneSequence ABSequence BA
Started1413
Completed1312
Not completed11
Withdrew: Adverse event01
Withdrew: Investigator's discretion10
Period 2 (AB: 11 Days, BA: 3 Days)
Participant flow — Period 2 (AB: 11 Days, BA: 3 Days)
MilestoneSequence ABSequence BA
Started1312
Completed1312
Not completed00

Outcome measures

PrimaryPharmacokinetic (PK) Parameter: AUClast of ATV, PRA, and ROS

AUClast is defined as the concentration of drug from time zero to the last observable concentration.

Time frame:
AB (Days 1,3,12,14) and BA (Days 6,8,18,20): Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 postdose; AB (Days 1,12) and BA (Days 6,18): 5,10,36 hours post dose; AB (Days 3,14) and BA (Days 8,20): 72 hours postdose
Reported as:
Mean · h*ng/mL
Pharmacokinetic (PK) Parameter: AUClast of ATV, PRA, and ROS
h*ng/mLAtorvastatinPravastatin + RosuvastatinFilgotinib + AtorvastatinFilgotinib + Pravastatin + Rosuvastatin
ATV78.8 ± 39.10—70.2 ± 27.08—
PRA—199.5 ± 115.64—232.5 ± 137.76
ROS—62.6 ± 29.03—89.3 ± 34.63
PrimaryPK Parameter: AUCinf of ATV, PRA, and ROS

AUCinf is defined as the concentration of drug extrapolated to infinite time.

Time frame:
AB (Days 1,3,12,14) and BA (Days 6,8,18,20): Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 postdose; AB (Days 1,12) and BA (Days 6,18): 5,10,36 hours post dose; AB (Days 3,14) and BA (Days 8,20): 72 hours postdose
Reported as:
Mean · h*ng/mL
PK Parameter: AUCinf of ATV, PRA, and ROS
h*ng/mLAtorvastatinPravastatin + RosuvastatinFilgotinib + AtorvastatinFilgotinib + Pravastatin + Rosuvastatin
ATV80.8 ± 39.76—71.8 ± 27.30—
PRA—201.3 ± 116.38—234.8 ± 137.43
ROS—66.0 ± 29.53—92.3 ± 34.94
PrimaryPK Parameter: Cmax of ATV, PRA, and ROS

Cmax is defined as the maximum observed concentration of drug.

Time frame:
AB (Days 1,3,12,14) and BA (Days 6,8,18,20): Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 postdose; AB (Days 1,12) and BA (Days 6,18): 5,10,36 hours post dose; AB (Days 3,14) and BA (Days 8,20): 72 hours postdose
Reported as:
Mean · ng/mL
PK Parameter: Cmax of ATV, PRA, and ROS
ng/mLAtorvastatinPravastatin + RosuvastatinFilgotinib + AtorvastatinFilgotinib + Pravastatin + Rosuvastatin
ATV19.7 ± 13.50—15.0 ± 7.81—
PRA—84.2 ± 56.60—99.2 ± 65.68
ROS—7.5 ± 4.17—12.3 ± 6.00
SecondaryPercentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant administered a study drug, which did not necessarily have a causal relationship with the treatment. AE was therefore any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug. TEAEs: AE with an onset date on or after the study drug start date and no later than 30 days after study drug stop date; or any AE leading to study drug discontinuation.

Time frame:
Sequence AB: First dose up to 47 days, Sequence BA: First dose up to 50 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
percentage of participantsAtorvastatinPravastatin + RosuvastatinFilgotinibFilgotinib + AtorvastatinFilgotinib + Pravastatin + Rosuvastatin
Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)19.224.065.47.711.5
SecondaryPercentage of Participants With Severity Grade 3 or Above Treatment-Emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were graded using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 of Adverse Events and Laboratory abnormalities. Laboratory abnormalities were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Life-threatening), Grade 5 (Death). Percentage of participants with Grade 3 or higher treatment-emergent laboratory abnormalities were reported.

Time frame:
Sequence AB: First dose up to 47 days, Sequence BA: First dose up to 50 days
Reported as:
Number · percentage of participants
Percentage of Participants With Severity Grade 3 or Above Treatment-Emergent Laboratory Abnormalities
percentage of participantsAtorvastatinPravastatin + RosuvastatinFilgotinibFilgotinib + AtorvastatinFilgotinib + Pravastatin + Rosuvastatin
Percentage of Participants With Severity Grade 3 or Above Treatment-Emergent Laboratory Abnormalities003.800

Adverse events

Collected over Adverse Events: Sequence AB: First dose up to 47 days, Sequence BA: First dose up to 50 days All Cause-Mortality: Sequence AB: From randomization up to 47 days, Sequence BA: From randomization up to 50 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atorvastatin0/27 (0%)0/26 (0%)2/26 (7.7%)
Pravastatin + Rosuvastatin0/27 (0%)0/25 (0%)4/25 (16%)
Filgotinib0/27 (0%)0/26 (0%)13/26 (50%)
Filgotinib + Atorvastatin0/27 (0%)0/26 (0%)2/26 (7.7%)
Filgotinib + Pravastatin + Rosuvastatin0/27 (0%)0/26 (0%)0/26 (0%)
Most frequent other events
Most frequent other events
EventAtorvastatinPravastatin + RosuvastatinFilgotinibFilgotinib + AtorvastatinFilgotinib + Pravastatin + Rosuvastatin
HeadacheNervous system disorders2/262/258/260/260/26
NauseaGastrointestinal disorders0/261/253/261/260/26
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/262/251/260/260/26
ConstipationGastrointestinal disorders0/260/252/261/260/26
MetrorrhagiaReproductive system and breast disorders0/260/252/260/260/26

Baseline characteristics

The Safety Analysis Set included all randomized participants who received at least 1 dose of any study drug.

Age, Continuous
Age, Continuous(years)Sequence ABSequence BATotal
Mean31 ± 7.229 ± 7.630 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)Sequence ABSequence BATotal
Female141226
Male011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence ABSequence BATotal
Hispanic or Latino011
Not Hispanic or Latino141226
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence ABSequence BATotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American325
White10919
More than one race000
Unknown or Not Reported112
08

Study locations

1 site
  • Prism Research, LLC
    Saint Paul, Minnesota 55114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jan 2021, 2 months.

Results were first posted in Jan 2022, 1 year after primary completion.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 2 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2020
First posted
Oct 29, 2020
StartActual
Nov 4, 2020
Primary completionActual
Jan 13, 2021
CompletionActual
Jan 13, 2021
Results first posted
Jan 19, 2022
Last update
Jun 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04608344
Lead sponsor
Gilead Sciences
Collaborators
Galapagos NV
Responsible party
Sponsor
First posted
Oct 29, 2020
Start date
Nov 4, 2020
Primary completion
Jan 13, 2021
Completion
Jan 13, 2021
Results posted
Jan 19, 2022
Last update
Jun 14, 2022

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion